|Bid||49.72 x 28400|
|Ask||49.73 x 2100|
|Day's range||49.43 - 51.76|
|52-week range||43.90 - 67.99|
|Beta (5Y monthly)||1.15|
|PE ratio (TTM)||11.48|
|Earnings date||08 Nov 2022|
|Forward dividend & yield||2.00 (3.88%)|
|Ex-dividend date||02 May 2022|
|1y target est||N/A|
The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration and visual impairment due to diabetic macular edema.
Supply chain shortages cost Bayer AG up to 3% of lost sales in its crop protection business this year, CEO Werner Baumann said on Wednesday, adding he expects constraints to continue in that segment and others. Global supply chains must rebalance before the situation eases, Baumann said in an interview with Reuters. "We do see shortages and we are affected by non-availability or insufficiency of products, that limits our ability to take advantage of the market opportunities that are out there," Baumann said.
(Bloomberg) -- Most Read from BloombergUS Inflation Tops Forecasts, Cementing Odds of Big Fed HikeUgly Selloff Pushes Stocks Down Most Since 2020: Markets WrapTerra Co-Founder Do Kwon Faces Arrest Warrant in South KoreaXi Returns to World Stage With Putin to Counter US DominanceThese Cities Have the Most Millionaires in New RankingBayer AG has quietly started the search for a successor to Chief Executive Officer Werner Baumann, raising the prospect of an early departure, according to people fami